Biocon Malaysia Gets EMA Approval for Insulin Fill-Finish Unit

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.8%Reaction day

₹434.35

prior close

₹438.40

announcement price

After-mkt

timing

Nifty Midcap 150market-0.4%+2.2% vs market

Pharmaceuticals peers, median of 164sector-0.1%+1.9% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Midcap 150 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-0.7

15m

-0.8

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.8-0.4+2.2-0.1+1.9

Next day

+0.5-0.8+1.3-1.0+1.5

+0.4-0.3+0.7-0.6+1.0

+1.4+0.1+1.4-0.5+1.9

+0.9-1.0+1.9-1.9+2.8

+0.6-1.9+2.5-2.8+3.4

+0.6-1.0+1.5-2.0+2.6

15d

+0.5+0.7-0.2-1.6+2.1

-5.1+1.3-6.4-1.2-4.0

-13.8-3.4-10.5-1.1-12.7

-19.6-6.1-13.5-3.3-16.3

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon's Malaysia facility received EMA approval for a new drug product fill finish line for Semglee (insulin glargine). Supplies to Europe from this new line are expected to start from Q2FY27. This expands Biocon's insulin manufacturing capacity and enables exports of its biosimilar insulin to European markets.

Likely market impact

Positive: new EMA-approved capacity supports European supply of Semglee from Q2FY27, aiding insulin business revenue growth.